All News

Officials with the FDA have granted Priority Review to Merck’s supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda) for use in combination with axitinib (Inlyta, Pfizer) as first-line treatment for advanced renal cell carcinoma (RCC).

Writing in The Journal of Infectious Disease, they noted that pregnant women tend to be treated as high-priority patients when it comes to influenza prevention and treatment, but they said there is relatively little evidence clarifying exactly how outcomes differ for pregnant women versus nonpregnant women.

In a new study, a team of investigators looked at data from a clinical trial testing 3 different ART regimens in order to determine the factors that can lead to enlarging waistlines in patients with HIV.

The history behind the soda fountain involves innovative pharmacists.

Jerry Garcia, of The Grateful Dead fame, was not only a good musician, he was a great entrepreneur with a lesson for pharmacists.

The study was aimed at the efficacy and safety of cerliponase alfa (Brineura, BioMarin) for patients with CLN2.

The ability to automate a medical benefit investigation is bringing new efficiencies to the hub and delivering better outcomes for providers, patients, and manufacturers.

Researchers have determined that many potentially adverse effects are not present on fact-based health care reviews.

Top news of the day across the health care landscape.

Sofosbuvir-based regimens for the treatment of hepatitis C were well tolerated in Asian American communities, according to a new study.

QS/1, a health care software solutions company, is partnering with Digital Pharmacist, Inc. to offer secure, HIPAA-compliant methods of patient communication through a variety of platforms.

Officials with the FDA have permitted marketing of the Tandem Diabetes Care t:Slim X2 insulin pump with interoperable technology (interoperable t:Slim X2) for delivering insulin under the skin for children and adults with diabetes.

The flu vaccine prevented 7.1 million illnesses, according to the analysis, along with 109,000 hospitalizations, and 8000 deaths, during the 2017-2018 influenza season.

Some pharmacists are not taking the time to stay hydrated and use the restroom, which can lead to serious health consequences.

A small mid-stage study demonstrated promising results for gene therapy candidate AMT-061 in patients with severe hemophilia B.

The trial evaluated margetuximab compared with trastuzumab, in combination with chemotherapy, for the treatment of HER 2-positive breast cancer.

Top news of the day across the health care landscape.

African Americans are disproportionately affected by HIV infection in the United States.

Those with hepatitis B virus have a significantly elevated risk for developing any type of age-related macular degeneration, according to a new report

Officials with the FDA have approved Novartis’ triclabendazole (Egaten) for the treatment of fascioliasis, also known as liver fluke infestation, in patients age 6 years and older.

Ryan, who was elected as the 54th Speaker of the House in 2015 and served in that role until January 2019 will speak as part of the Business Program, scheduled for Tuesday April 30.

An FDA program is seeking to facilitate better quality drug manufacturing through recognized consensus standards.

A new FDA program aims to facilitate better quality drug manufacturing through recognized consensus standards.

Amid a global measles outbreak, some teenagers are questioning their anti-vaxxer parents about not vaccinating them against many dangerous and deadly diseases.

Top news of the day across the health care landscape.

For fourth-year residency candidates across the nation, January through March is often a whirlwind of presentations, program overviews, panels, and a plethora of questions.

Phase 3 trial evaluating isatuximab in combination with standard of care met the primary endpoint of prolonging progression-free survival.

If approved, apalutamide (Erleada) plus androgen deprivation therapy would offer an additional treatment option for patients with metastatic castration-sensitive prostate cancer.